Gene editing technologies and therapeutic genome engineering
Latest Research Highlights
From November 2025
CRISPR technologies face challenges in immunocompetent models, impacting target identification, ref: Saini doi.org/10.1016/j.cell.2025.10.007/
A Phase 1 trial of CTX310 showed no dose-limiting toxic effects, indicating safety in gene editing targeting ANGPTL3, ref: Laffin doi.org/10.1056/NEJMoa2511778/
Recurrent mutations in mitochondrial rRNA genes were identified across 14,106 tumor genomes, suggesting their role in cancer biology, ref: Boscenco doi.org/10.1038/s41588-025-02374-0/
The Paneth-like transition in colorectal cancer cells contributes to resistance against dual KRAS and EGFR targeting, ref: Zhang doi.org/10.1016/j.ccell.2025.10.010/
FAM114A1 orchestrates immune evasion in triple-negative breast cancer, highlighting mechanisms of resistance to immunotherapy, ref: Zhang doi.org/10.1038/s41392-025-02472-9/
Metagenomic Editing (MetaEdit) enables in vivo modification of commensal bacteria, showcasing advancements in microbiome engineering, ref: Gelsinger doi.org/10.1126/science.adx7604/
RMPore provides a comprehensive database for RNA modifications detected by Nanopore sequencing, facilitating research in post-transcriptional regulation, ref: Lin doi.org/10.1093/nar/
The PERK/MAT2A/PDGFB axis supports circulating tumor cell cluster survival, revealing adaptive mechanisms in metastasis, ref: Tang doi.org/10.1002/cac2.70072/